Moxonidine Biogaran (Moxonidine)

Moxonidine activates imidazoline I1 receptors in the brainstem, which reduces sympathetic nervous system activity. This leads to decreased release of norepinephrine, lowering peripheral vascular resistance and cardiac output, ultimately resulting in reduced blood pressure.

The dosage of Moxonidine Biogaran is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength and titration schedule.

Safety of moxonidine in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, differing from ACE inhibitors, ARBs, beta‑blockers and calcium‑channel blockers. It primarily reduces sympathetic outflow, which can be advantageous in patients who need an additional mechanism beyond conventional vasodilation or renin‑angiotensin blockade.

Moxonidine tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain stability throughout their shelf life.

Moxonidine Biogaran is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water, and patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include severe hypotension, bradycardia, allergic reactions such as rash or angioedema, and rare liver enzyme elevations. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of an allergic response.

Moxonidine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnancy unless absolutely necessary.